Acromegaly

• FDA approval · 2007-08-30
  FDA Approved: SOMATULINE DEPOT — Original Application (Ipsen Biopharmaceuticals, Inc.)

  The FDA approved Somatuline Depot (lanreotide acetate) under the Original Application for Ipsen Biopharmaceuticals.

• CLINICAL_TRIALS trial_result · 2007-04-17
  Clinical Trial Update: Dose Escalation of Octreotide-LAR as First-Line Therapy in Resistant Acromegaly [Phase 4]

  Phase 4 trial update evaluating dose escalation of Octreotide-LAR as first-line therapy in resistant acromegaly; the study is reported as co…

• CLINICAL_TRIALS trial_result · 2006-09-08
  Clinical Trial Update: Comparable Effects of Lanreotide Autogel and Octreotide LAR on GH, IGF-I Levels and Patient Satisfaction [Phase 4]

  Phase 4 trial comparing lanreotide Autogel and octreotide LAR in acromegaly found comparable effects on GH and IGF-I levels and patient sati…

• FDA approval · 2006-08-15
  FDA Approved: BROMOCRIPTINE MESYLATE — Supplemental Application (Mylan Pharmaceuticals Inc.)

  FDA approval of a supplemental application for a generic bromocriptine mesylate product by Mylan Pharmaceuticals Inc.

• CLINICAL_TRIALS research · 2006-05-26
  Clinical Trial Update: Estrogen Treatment in Acromegalic Women [Phase 2]

  Phase 2 clinical trial investigating estrogen treatment in women with acromegaly; the current trial status is unknown.

• Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.